Is autologous orthobiologic therapy safe?

Autologous, patient-derived orthobiologic procedures have a favorable safety profile when performed using sterile technique, appropriate patient selection, and image-guided delivery. Because the biologic material is derived from the patient’s own tissues, the risk of immunologic rejection is minimal.

Published clinical literature evaluating autologous bone marrow– and adipose-derived cell-containing biologic products has not demonstrated an increased incidence of malignancy attributable to these therapies when used appropriately. As with any medical procedure, risks exist and are discussed in detail during the informed consent process.

Who may be a candidate for autologous orthobiologic therapy?

Patients with chronic musculoskeletal pain involving joints, bone, tendons, or ligaments who have not achieved adequate relief with conservative treatments may be considered for evaluation. Candidacy depends on diagnosis, injury chronicity, imaging findings, overall health status, and patient goals.

Patients with mild to moderate osteoarthritis may experience improvements in pain and function following autologous biologic interventions. In advanced or end-stage osteoarthritis, the potential for structural tissue restoration is limited; however, some patients may still experience symptomatic benefit. Partial tendon or ligament injuries without significant retraction are also commonly evaluated for biologic treatment.

How is candidacy determined?

Candidacy is determined through a comprehensive clinical consultation, which includes a detailed history, physical examination, and review of prior imaging such as MRI or radiographs. If appropriate imaging has not been obtained, it may be ordered to better characterize the injury and guide treatment planning.

Does Boulder Biologics adhere to FDA guidance?

Yes. All autologous orthobiologic procedures are structured to align with applicable FDA guidance regarding human cells, tissues, and cellular- and tissue-based products (HCT/Ps), including considerations of minimal manipulation and homologous use under Section 361 of the Public Health Service Act and 21 CFR Part 1271, where applicable.

Is the procedure painful?

Discomfort varies depending on the anatomic site treated and individual pain tolerance. Local anesthetics are used to minimize procedural discomfort, and oral anxiolytic or sedative medication may be prescribed when appropriate. Certain harvest and injection sites may be more uncomfortable than others.

Will I experience pain after the procedure?

Post-procedural pain and soreness are expected once local anesthetics wear off and may range from moderate to significant depending on the treatment site. This response is part of the inflammatory phase of tissue repair. Patients receive detailed post-procedure instructions and may contact the clinic if they have any concerns regarding pain management.

Can multiple injury sites be treated in one visit?

In selected cases, multiple anatomic sites may be treated during a single visit. This determination is made on an individual basis, taking into account procedural complexity, patient tolerance, and safety considerations.

How effective are autologous orthobiologic therapies?

Clinical response varies among patients. Many individuals experience meaningful improvements in pain and function, while others may have partial or limited benefit. Outcomes depend on injury type, severity, chronicity, biologic product selection, and patient-specific factors. No outcome can be guaranteed.

Why might results take several months?

Autologous biologic therapies act through biologically mediated repair processes rather than immediate structural correction. Improvements typically evolve over several months, with many patients noticing progressive changes between three and six months following treatment.

Is infection a risk?

Infection is an uncommon but possible risk associated with any invasive procedure. Strict sterile technique, image guidance, and controlled processing environments are used to minimize this risk. Patients are instructed to monitor for signs of infection, including fever, chills, increasing redness, swelling, or worsening pain at the treatment site, and to contact the clinic promptly if symptoms occur.

Does insurance cover autologous orthobiologic therapy?

At present, most autologous orthobiologic procedures are not covered by insurance plans. Coverage policies vary, and patients are encouraged to discuss financial considerations with clinic staff during consultation.

Why use both bone marrow–derived and adipose-derived autologous biologic products in the same joint?

Bone marrow aspirate concentrate (BMAC) and adipose-derived autologous biologic products differ in cellular composition, signaling profiles, and extracellular matrix (ECM) characteristics. When clinically appropriate, combining these biologic sources allows complementary biologic mechanisms to be delivered to a single joint environment.

Bone marrow–derived biologic products
Bone marrow aspirate concentrate contains a heterogeneous mixture of nucleated cells, including hematopoietic cells, stromal cells, progenitor populations, platelets, and immune-modulating factors. Within this mixture, mesenchymal stromal cell–enriched populations are present at low frequencies. Current evidence suggests that the clinical activity of BMAC is primarily mediated by paracrine signaling, immunomodulation, and support of local repair processes, rather than by direct differentiation into cartilage or other tissues.

Bone marrow–derived biologic products are also rich in cytokines and growth factors that may influence inflammation, angiogenesis, and cellular recruitment within subchondral bone and the osteochondral unit, which is increasingly recognized as a critical contributor to osteoarthritis-related pain and dysfunction.

Adipose-derived autologous biologic products
Adipose tissue–derived biologic products typically contain a higher concentration of stromal and progenitor cells per unit volume compared with native bone marrow aspirate. Importantly, adipose tissue also provides a distinct extracellular matrix environment and secretory profile that may support tissue homeostasis and repair.

Emerging research highlights the role of extracellular matrix components in supporting chondrocyte function, cartilage integrity, and biomechanical signaling. Rather than serving as a direct source of cartilage replacement, adipose-derived biologic products may provide structural and biochemical cues that support endogenous repair mechanisms.

In comparative proteomic analyses, Amable and colleagues demonstrated that adipose-derived mesenchymal stromal cells secrete higher levels of several extracellular matrix proteins, including collagens I, II, III, and IV, compared with mesenchymal stromal cells derived from other tissue sources. Collagen II is a major structural component of hyaline cartilage, underscoring the relevance of ECM composition in cartilage-related applications.

Rationale for combined use
The clinical rationale for combining bone marrow–derived and adipose-derived autologous biologic products is not based on claims of enhanced “stem cell differentiation” or guaranteed cartilage regeneration. Rather, it reflects an evidence-informed strategy to deliver complementary biologic signals and matrix components that may better support the joint microenvironment.

Bone marrow–derived products may preferentially support subchondral bone, inflammatory modulation, and osteochondral signaling. In contrast, adipose-derived products may contribute ECM-related support and paracrine factors relevant to cartilage and soft tissue homeostasis. When used together in large joints, these biologic sources may provide a broader spectrum of biologic activity than either source alone.

Regulatory considerations
All biologic materials used are autologous and patient derived. Processing and clinical use are structured to align with applicable FDA guidance regarding minimal manipulation and homologous use under 21 CFR Part 1271, where appropriate. No claims are made regarding exogenous cell replacement, engineered tissue formation, or unapproved biologic activity.

Treatment decisions are individualized and based on clinical evaluation, imaging findings, and patient-specific factors. As with all autologous orthobiologic procedures, outcomes vary and cannot be guaranteed.

What is the difference between autologous mesenchymal stromal cell–containing biologic products, fetal tissue–derived products, and embryonic stem cells? Is one “better” than the other?

These biologic materials differ fundamentally in source, composition, regulatory status, ethical considerations, and clinical applicability. They are not interchangeable, and none can be considered universally “better” across all contexts.

Autologous mesenchymal stromal cell–containing biologic products Autologous biologic products are derived from a patient’s own tissues, most commonly bone marrow or adipose tissue, and are processed and administered within a defined clinical workflow. These products contain heterogeneous cell populations, including mesenchymal stromal cell–enriched fractions, hematopoietic cells, immune cells, platelets, and associated signaling molecules.

Current scientific evidence indicates that the clinical activity of autologous bone marrow– and adipose-derived biologic products is mediated primarily through paracrine signaling, immunomodulation, and support of the local tissue microenvironment rather than direct cell replacement or differentiation. Because the tissue source is autologous, risks related to immune incompatibility and disease transmission are minimized.

At Boulder Biologics, clinical procedures are limited to autologous, patient-derived biologic products. We do not use embryonic stem cells or donor-derived fetal tissues in outpatient clinical care.

Fetal tissue–derived products (perinatal tissues)
Fetal or perinatal tissue–derived products may be sourced from donated umbilical cord tissue, cord blood, placenta, chorion, or amniotic fluid. These products are often processed, cryopreserved, and distributed commercially.

A critical issue with many perinatal tissue products marketed in outpatient settings is inappropriate labeling as “stem cell therapies.” In most commercially available preparations, the products are acellular or contain very low numbers of viable cells at the time of administration. Their biologic activity, when present, is generally attributable to residual extracellular matrix components or soluble factors rather than live stem cells.

From a regulatory perspective, many perinatal tissue products have been the subject of FDA enforcement actions when marketed with unsupported claims or when failing to meet criteria for minimal manipulation and homologous use. Their clinical use, regulatory classification, and safety profile differ substantially from autologous same-day biologic procedures.

Embryonic stem cells
Embryonic stem cells are derived from early-stage embryos and are characterized by pluripotency, meaning they have the theoretical ability to differentiate into cell types from all three germ layers. Their use raises well-established ethical considerations and is subject to strict regulatory oversight.

From a clinical standpoint, embryonic stem cells carry significant safety concerns, including the risk of uncontrolled proliferation and tumor formation (teratomas). For these reasons, embryonic stem cells are not used in routine outpatient clinical care and are limited to tightly controlled research settings.

Is one approach better than another? No biologic source can be universally defined as “better.” Each differs in risk profile, regulatory status, ethical considerations, and intended use. In outpatient musculoskeletal and orthobiologic care, autologous, patient-derived biologic products are currently the most appropriate option when biologic therapies are considered, given their safety profile, regulatory clarity, and compatibility with same-day clinical workflows.

Importantly, claims that any biologic product represents a “standard of care” for regenerative medicine should be interpreted cautiously. Orthobiologic therapies remain an evolving field, and treatment decisions should be individualized, evidence-informed, and grounded in transparent discussion of known benefits, limitations, and uncertainties.

Regulatory Disclaimer
The biologic procedures described on this website involve autologous, patient-derived human cells and tissues. These products have not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of osteoarthritis or other musculoskeletal conditions. The FDA regulates human cells, tissues, and cellular- and tissue-based products (HCT/Ps) under 21 CFR Part 1271 and has issued public guidance and enforcement actions related to the marketing and clinical use of regenerative medicine products. No claims are made regarding guaranteed outcomes, tissue regeneration, or disease modification. Clinical use is based on physician judgment, current scientific understanding, and individual patient evaluation.

Who should perform orthopedic stem cell treatments?

Autologous orthobiologic procedures should be performed by appropriately trained and licensed physicians with advanced expertise in musculoskeletal diagnosis, image-guided interventions, and biologic handling. These procedures involve invasive tissue harvest, biologic processing, and precise delivery to complex anatomic structures, all of which require a high level of clinical judgment and technical skill.

Physician qualifications and training. Medical Doctors (MDs) and Doctors of Osteopathic Medicine (DOs) are uniquely trained to evaluate musculoskeletal pathology, interpret advanced imaging, manage procedural risks, and respond to complications should they arise. In the context of orthobiologic care, this includes expertise in:
• Musculoskeletal anatomy and pathology
• Image-guided procedures using ultrasound and fluoroscopy
• Sterile technique and biologic handling
• Appropriate patient selection and informed consent
• Recognition and management of adverse events

Because autologous orthobiologic procedures involve tissue harvest (e.g., bone marrow or adipose), biologic processing, and targeted injection into joints, bone, or soft tissues, they fall squarely within the practice of medicine and should be overseen and performed by qualified physicians.

Role of non-physician providers
Non-physician clinicians may play important roles in patient care, education, and procedural support; however, the independent performance of orthobiologic harvests and injections by non-physicians raises concerns related to training, scope of practice, and patient safety. Incorrect tissue harvest, improper biologic handling, or inaccurate injection placement can reduce potential benefit and increase the risk of complications.

Evidence from interventional orthopedics and pain medicine consistently demonstrates that accurate, image-guided delivery is a critical determinant of procedural safety and outcomes. Misplacement of biologic material may result in ineffective treatment or unintended tissue injury.

Importance of image guidance and experience. Orthobiologic procedures should be performed using real-time imaging modalities such as ultrasound and/or fluoroscopy to ensure accurate localization, avoid neurovascular structures, and confirm appropriate anatomic delivery. Experience with these modalities is essential, particularly for procedures involving the subchondral bone, deep joints, or peri-tendinous and peri-neural structures.

At Boulder Biologics, procedures are performed by a physician with extensive experience in image-guided musculoskeletal interventions and autologous biologic therapies, with protocols designed to emphasize safety, precision, and regulatory awareness.

Regulatory Disclaimer. Autologous orthobiologic procedures described on this website involve invasive medical interventions and the use of patient-derived human cells and tissues. These procedures are not approved by the U.S. Food and Drug Administration (FDA) for the treatment of osteoarthritis or other musculoskeletal conditions. The FDA regulates human cells, tissues, and cellular- and tissue-based products (HCT/Ps) under 21 CFR Part 1271 and has emphasized that such procedures should be performed by appropriately qualified medical professionals within the scope of licensed medical practice. No claims are made regarding guaranteed outcomes, and clinical decisions are based on physician judgment, current scientific understanding, and individual patient evaluation.

Does Boulder Biologics offer intravenous (IV) and intranasal autologous biologic therapies?

Yes. Boulder Biologics offers intravenous (IV) and intranasal administration of autologous, patient-derived cell-containing biologic products under a regulatory framework reviewed by the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER).

Following submission of an Investigational New Drug (IND) application, CBER determined that our biologic processing and administration protocols for IV bone marrow aspirate (BMA) and intranasal bone marrow aspirate concentrate (BMAC) qualify for the Same Surgical Procedure Exception (SSPE) under 21 CFR 1271.15(b), as the tissues are autologous, minimally manipulated, and returned to the same individual during the same surgical procedure.

Bone marrow aspirate filtration and safety considerations. Prior to IV or intranasal administration, bone marrow aspirate is filtered using defined pore-size filtration to remove larger cellular aggregates, bone fragments, clots, and debris that may be present following aspiration. This step is performed to:
• Reduce the presence of large cells or aggregates that could impair microvascular passage
• Eliminate bone fragments and clot material introduced during aspiration
• Improve uniformity of the infused biologic preparation
• Enhance procedural safety while preserving viable mononuclear and stromal cell populations

Filtration does not constitute cell expansion or genetic manipulation and is consistent with minimal manipulation under same-day processing workflows. Importantly, this step further distinguishes same-day, ex vivo BMA preparations from culture-expanded cellular products evaluated in much of the IV MSC literature.

Clarifying the pulmonary “first-pass effect”
Reports of pulmonary sequestration following IV administration of mesenchymal stromal cells largely arise from studies using culture-expanded MSCs, which are significantly larger in diameter than freshly isolated marrow-derived cells and may exceed pulmonary capillary dimensions, leading to mechanical entrapment.

In contrast, fresh, ex vivo MSC-enriched populations isolated from filtered, same-day BMA are smaller, heterogeneous, and phenotypically distinct from expanded MSC products. When appropriately filtered and administered under same-day protocols, these cells are not subject to the same degree of pulmonary trapping described in expansion-based studies.

Furthermore, IV administration of same-day BMA is not intended to achieve targeted cellular engraftment, but rather to support systemic immunomodulatory and paracrine signaling, which may be relevant in selected inflammatory, neurologic, or systemic conditions.

Orthopedic vs systemic delivery considerations
For focal musculoskeletal conditions involving joints, tendons, ligaments, or subchondral bone, direct, image-guided delivery of autologous biologic material remains the most anatomically and biologically appropriate approach. IV administration is not presented as a substitute for orthopedic injection and should not be marketed as such.

Neurologic and vascular safety considerations
Concerns in the literature regarding microvascular obstruction and embolic risk are predominantly associated with intra-arterial administration and/or culture-expanded cellular products. Boulder Biologics does not perform intra-arterial delivery of cellular biologics. IV and intranasal routes are used selectively, with protocols designed to minimize vascular risk and remain consistent with same-day, minimally manipulated use.

Source and processing of biologic material
All IV and intranasal biologic preparations offered at Boulder Biologics are derived exclusively from autologous bone marrow aspirate or bone marrow aspirate concentrate, processed using same-day protocols without cell expansion, genetic modification, or prolonged culture.

Regulatory Disclaimer
The autologous biologic procedures described on this website involve patient-derived human cells and tissues processed and administered under the Same Surgical Procedure Exception (21 CFR 1271.15(b)), as determined by the FDA Center for Biologics Evaluation and Research (CBER). The FDA has not approved these products for the treatment of specific diseases or conditions. Clinical use is based on physician judgment, current scientific understanding, and individualized patient evaluation. No claims are made regarding guaranteed outcomes, tissue regeneration, or disease modification.

What is flow cytometry, and how is it used in autologous orthobiologic procedures? Does Boulder Biologics use flow cytometry?

Flow cytometry is a laboratory analytical technique that uses laser-based optics to rapidly analyze individual cells in suspension. By measuring light scatter and fluorescence emitted from labeled cells, flow cytometry enables quantitative assessment of cell populations, including total nucleated cell counts, cell viability, and the relative frequency of specific cell subsets based on surface marker expression.

In the context of autologous orthobiologic procedures, flow cytometry is used as a characterization and quality assessment tool. It is not used to modify cells, engineer tissues, or predict clinical outcomes.

How Boulder Biologics uses flow cytometry
Boulder Biologics employs an in-house Sysmex XF-1600 flow cytometer to analyze live samples of bone marrow aspirate (BMA), bone marrow aspirate concentrate (BMAC), and related fractions. This platform allows for standardized, reproducible cellular analysis performed under controlled laboratory conditions.

Using flow cytometry, we are able to:
• Quantify total nucleated cell counts in BMA and BMAC
• Assess cell viability using validated membrane-integrity dyes
• Characterize MSC-enriched populations in freshly isolated samples using evidence-supported marker strategies (e.g., CD271⁺, TNAP⁺ with lineage exclusion)
• Compare native aspirate, concentrated product, and residual fractions as an internal quality control measure

These analyses help verify that biologic processing preserves cell viability and achieves enrichment patterns consistent with published scientific literature.

Informed consent for flow cytometry analysis
Flow cytometric analysis is performed only when a patient has provided informed consent for a portion of their autologous sample to be used for laboratory characterization. Consent is obtained as part of the clinical intake and informed consent process and clearly explains:
• The purpose of flow cytometry as a characterization and quality assessment tool
• That only a small aliquot of the patient’s sample is used
• That analysis does not alter the clinical biologic product
• That results are informational and not predictive of treatment outcomes

Patients may decline laboratory analysis without affecting their eligibility for clinical care.

What flow cytometry is not used for. Flow cytometry:
• Does not guarantee clinical efficacy or predict individual patient outcomes
• Does not establish a required or optimal “stem cell dose”
• Does not imply tissue regeneration, differentiation, or engraftment

Instead, it provides transparency and scientific rigor by documenting the cellular composition and viability of autologous biologic material at the time of use.

Does Boulder Biologics provide flow cytometry data to patients?

Yes. When flow cytometry is performed, Boulder Biologics can provide patient-specific flow cytometry summaries describing nucleated cell counts, viability, and MSC-enriched population metrics. These results are reviewed in context and are intended for documentation and informational purposes.

Regulatory context
Flow cytometric analysis is used solely for cellular characterization and quality assessment. It does not constitute more than minimal manipulation, does not modify the biologic material, and is consistent with FDA expectations regarding transparency in the handling of human cells and tissues under applicable regulatory frameworks.